Aquestive Therapeutics vs ARS Pharmaceuticals
AQST and SPRY side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AQST and SPRY compare
Aquestive Therapeutics is the larger company, worth 1.3 times as much as ARS Pharmaceuticals ($464M against $363M).
Aquestive Therapeutics grew revenue faster over the last twelve months (22.6% versus 4.1% for ARS Pharmaceuticals).
Aquestive Therapeutics keeps more of each dollar of sales as profit, with a net margin of −145% compared with −184% at ARS Pharmaceuticals.
ARS Pharmaceuticals scores higher on the StockData Score (8 against 3 for Aquestive Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AQST | SPRY |
|---|---|---|
| Size and price | ||
| Market cap | $464M | $363M |
| Share price | $3.70 | $3.65 |
| Change, 1 year | −31.4% | −55.5% |
| Change, 5 years | −41.9% | −49.2% |
| Beta (5Y) | 1.20 | 3.64 |
| Employees | 147 | 158 |
| StockData Score | ||
| Total score | 3 | 8 (better) |
| Valuation score | 0 | 0 |
| Growth score | 2 | 2 |
| Performance score | 0 | 1 (better) |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 8.6× | 3.1× (better) |
| P/B | – | 29.0× |
| FCF yield | −9.9% (better) | −54.2% |
| Growth | ||
| Revenue growth (TTM) | 22.6% (better) | 4.1% |
| Revenue growth, 5Y average | −0.58% | – |
| Profitability | ||
| Gross margin | 67.0% | – |
| Operating margin | −97.5% (better) | −185% |
| Net margin | −145% (better) | −184% |
| FCF margin | −85.0% (better) | −168% |
| Return on equity | – | −210% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −4.7× | – |
| Current ratio | 7.19 (better) | 3.48 |
| Altman Z-score | −3.57 | −3.09 (better) |
| Piotroski F-score | 2 | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 57.4% | 91.2% |
| Held by insiders | 3.2% | 46.7% |
| Insider net buying, 12 months | −$2.3M | −$284K (better) |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 24.1% | 35.9% |
Go deeper
- AQST stock overview
- AQST income statement
- AQST valuation and score
- SPRY stock overview
- SPRY income statement
- SPRY valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.